Effects of delayed intraventricular TLR7 agonist administration on long-term neurological outcome following asphyxia in the preterm fetal sheep

Kenta H. T. Cho1, Nina Zeng1, Praju V. Anekal2, Bing Xu1,3 & Mhoyra Fraser1

In the preterm brain, accumulating evidence suggests toll-like receptors (TLRs) are key mediators of the downstream inflammatory pathways triggered by hypoxia-ischemia (HI), which have the potential to exacerbate or ameliorate injury. Recently we demonstrated that central acute administration of the TLR7 agonist Gardiquimod (GDQ) confers neuroprotection in the preterm fetal sheep at 3 days post-asphyxial recovery. However, it is unknown whether GDQ can afford long-term protection. To address this, we examined the long-term effects of GDQ. Briefly, fetal sheep (0.7 gestation) received sham asphyxia or asphyxia induced by umbilical cord occlusion, and were studied for 7 days recovery. Intracerebroventricular (ICV) infusion of GDQ (total dose 3.34 mg) or vehicle was performed from 1–4 hours after asphyxia. GDQ was associated with a robust increase in concentration of tumor necrosis factor-α (TNF-α) in the fetal plasma, and interleukin-10 (IL-10) in both the fetal plasma and cerebrospinal fluid. GDQ did not significantly change the number of total and immature/mature oligodendrocytes within the periventricular and intragryral white matter. No changes were observed in astroglial and microglial numbers and proliferating cells in both white matter regions. GDQ increased neuronal survival in the CA4 region of the hippocampus, but was associated with exacerbated neuronal injury within the caudate nucleus. In conclusion, our data suggest delayed acute ICV administration of GDQ after severe HI in the developing brain may not support long-term neuroprotection.

Preterm birth is closely associated with long-term neurodevelopmental disability. While survival rates among preterm infants have significantly improved, rates of neonatal morbidity remain high with 50% of extremely preterm infants displaying cognitive and behavioural difficulties. The etiology of preterm brain injury is multifactorial, however a key contributing factor is the greater occurrence of acute hypoxic ischemicencephalopathy (HIE) in moderately preterm infants compared to term. Therapeutic mild hypothermia is now standard care for term newborns after moderate to severe HIE. Despite its benefits, mild hypothermia is not recommended for preterm infants <35 weeks gestational age. Thus, there is a considerable unmet need for neuroprotective therapies for preterm infants with acute HIE.

Growing evidence suggests that inflammation plays a critical role in the pathogenesis of HIE and immunomodulatory drugs have therapeutic promise. Toll-like receptors (TLRs) are key regulators of the initial inflammatory response to HI, and while implicated in brain injury, they can be neuroprotective via tolerance (pre-conditioning) and immunomodulation. The TLR7 signaling pathway can modulate both pro- and anti-inflammatory responses in central and peripheral immune cells, with the potential to reduce inflammatory injury within the CNS. We have previously shown that pre-conditioning with the inflammatory mediator lipopolysaccharide (LPS) before an hypoxic-ischemic (HI) insult in the preterm fetal sheep reduced preterm brain injury, in association with upregulation of TLR7 gene expression and both central and peripheral induction of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in the control group. In an adult mouse model of stroke, pre-insult exposure to the TLR7 agonist Gardiquimod...
(GDQ) reduced cerebral infarct size\(^{20}\). Further, we have reported that intracerebroventricular (ICV) infusion of GDQ following asphyxia in the preterm fetal sheep significantly improved oligodendrocyte survival within the white matter and subcortical neurons after 3 days post-asphyxial recovery\(^{21}\). Additionally, neuroprotection was associated with induction of immunosuppressive M2c-like microglia (cluster of differentiation 163; CD163 immunoreactive microglia) within the white matter and significant elevations in the systemic concentration of anti-inflammatory cytokines IFN-\(\gamma\) and interleukin-10 (IL-10). However, HI brain injury can evolve over days and even weeks\(^{22,23}\). Indeed, evidence from several animal models of perinatal brain injury suggest cell death typically occurs during the secondary phase of injury, and is often followed by a chronic or tertiary phase of injury characterized by progressive cell death and remodeling\(^{24,25}\). Thus, the purpose of this study was to evaluate the effect of delayed GDQ administration on cerebral white and grey matter 7 days after an acute HI insult \textit{in utero} in 0.7 gestation preterm fetal sheep. Neural development of the preterm fetal sheep at this gestational age is broadly equivalent to human brain development at 28–32 weeks gestation\(^{26}\).

**Methods**

**Animals and surgical preparations.** All animal experiments were performed according to procedures approved by the Animal Ethics Committee of The University of Auckland. This study complies with the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines, developed by the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)\(^{27}\). Romney– Suffolk cross fetal sheep were instrumented at 98–99 days of gestation (term \(\sim 147\) days gestation). Ewes were anesthetized by an intravenous injection of propofol (5 mg/kg; AstraZeneca Limited, Auckland, New Zealand), and general anesthesia was maintained using 2–3% isoflurane in O\(_2\). Ewes received 5 ml of Streptokinase (250,000 IU/ml procaine penicillin and 250 mg/ml dihydromyostreptomycin; Stockguard Labs, Hamilton, New Zealand) intramuscularly for prophylaxis, 30 minutes before the start of surgery. During surgery, maternal fluid balance was maintained with constant saline infusion (250 ml/h), and the depth of anesthesia, maternal heart rate and respiration in the ewes were constantly monitored by trained anesthetic staff.

Using aseptic techniques, maternal paramedian abdominal and uterotomy incisions were performed to exteriorize the head, neck, and forelimbs of the fetus. Polyvinyl catheters were placed into both left and right brachial arteries of the fetus for pre-ductal blood sampling and mean arterial pressure (MAP) measurements. A further catheter was placed into the amniotic sac and secured to the fetal torso to enable monitoring of intra-amniotic pressure as a reference for fetal blood pressure. A further pair of electrodes was placed subcutaneously over the right shoulder and chest at apex level and sewn across the chest to measure fetal electrocardiogram (ECG). Electroencephalogram (EEG) electrodes were placed on the dura over the parasagittal parietal cortex (5 and 10 mm anterior to the bregma and 5 mm lateral), and a reference electrode placed over the occiput. An ICV catheter was placed into the left lateral ventricle (6 mm anterior and 4 mm lateral to bregma) for infusion of GDQ (Invivogen, San Diego, CA, USA). An inflatable silicone occluder (OC16HD, 16 mm, In Vivo Metric, Healdsburg, CA, USA) was placed loosely around the umbilical cord for reversible post-surgical umbilical cord occlusions.

On completion of surgical procedures, the fetus was returned to the uterus and any amniotic fluid loss replenished with warm sterile saline. Thereafter, antibiotics (80 mg Gentamicin, Pharmacia and Upjohn, Rydalmere, New South Wales, Australia) was administered into the amniotic sac and the uterus closed. On closure of the maternal laparotomy incision, the surrounding tissue was infiltrated with a local analgesic, 10 ml 0.5% bupivacaine plus adrenaline (AstraZeneca Ltd., Auckland, New Zealand). All electrode leads and polyvinyl catheters were exteriorized through a trocar hole in the maternal flank. A polyvinyl catheter was inserted into the maternal abdomen to provide access for post-operative maternal care and euthanasia. All methodology has been described previously\(^{28}\).

**Post-operative care.** Following surgery, animals were housed together in individual metabolic cages. Rooms were temperature-controlled (16 ± 1 °C, humidity 50 ± 10%) with a 12 hour light/dark cycle. Ewes were provided with water and food \textit{ad libitum}.

A period of at least 4–5 days recovery was allowed before commencement of experiments. Antibiotics were given intravenously to the ewe each day for 3 days; 600 mg Crystapen (benzylpenicillin sodium, Novartis, Auckland, New Zealand) and 80 mg Gentamicin (Pharmacia and Upjohn, Rydalmere, New South Wales, Australia) was administered to the amniotic sac and the uterus closed. On closure of the maternal laparotomy incision, the surrounding tissue was infiltrated with a local analgesic, 10 ml 0.5% bupivacaine plus adrenaline (AstraZeneca Ltd., Auckland, New Zealand). All electrode leads and polyvinyl catheters were exteriorized through a trocar hole in the maternal flank. A polyvinyl catheter was inserted into the maternal saphenous vein to provide access for post-operative maternal care and euthanasia. All methodology has been described previously\(^{28}\).

**Physiological monitoring.** Fetal MAP (Novatrans II, MX860; Medex, Hilliard, OH, USA), corrected for maternal movement by subtraction of amniotic fluid pressure, fetal heart rate (FHR) derived from the ECG, EEG and temperature were recorded continuously from 24 hours before occlusion (102–103 days gestation) until post-mortem (110–111 days gestation) as previously described\(^{19,28}\). Physiological data is not reported as part of the present study.

**Experimental protocol.** On day 103–104 of gestation, animals were randomly assigned to either sham asphyxia (n = 8), asphyxia + vehicle (n = 7) or asphyxia + GDQ (n = 7) groups. Umbilical cord occlusion (UCO) was induced at 07.30 hours by rapid complete inflation of the umbilical cord occluder for 25 minutes or until blood pressure fell below 8 mmHg or there was fetal asystole\(^{29,30}\). Sham control animals received no occlusion. This UCO paradigm is associated with diffuse white matter injury and moderate subcortical neuronal loss\(^{31,32}\), comparable to that observed in preterm infants\(^{42}\).
The TLR7 ligand, GDQ, was infused into the lateral ventricle of fetuses (asphyxia + GDQ group) using a CMA-100 microinjection pump (Carnegie Medicin, AB, Stockholm, Sweden). Fetuses received a primed continuous infusion of 3.34 mg of GDQ (InvivoGen, San Diego, CA, USA, 1.67 mg/ml, equivalent to approximately 1.8 mg/kg of fetal body weight) dissolved in 2 ml of sterile endotoxin-free modified artificial cerebrospinal fluid (aCSF) at a rate of 11.1 μl/minutes for 3 hours commencing from 1 to 4 hours after the end of occlusion. This dose was based on evidence of neuroprotection in adult stroke models and has been recently shown to be neuroprotective in our fetal sheep model. The asphyxia + vehicle animals received an infusion of vehicle alone (aCSF) using the same infusion protocol. Fetal arterial blood samples were collected for measurement of pH, blood gases, glucose and lactate values before (baseline, -30 minutes), during (5 and 17 minutes) and following UCO (1, 4, 6, 24, 72, 96, 120, 144 and 168 hours). Seven days after occlusion, ewes and fetuses were killed by an overdose of sodium pentobarbital intravenously to the ewe (9 g Pentobarb 300, Chemstock International, Christchurch, New Zealand). Fetuses were weighed and sexed. Fetals brains were perfusion fixed in situ with 500 ml endotoxin-free heparinized saline followed by 1000 ml of 10% phosphate-buffered formalin, pH 7.4. The fetal brain was removed from the skull and post-fixed in the same fixative for approximately 5 days, then divided into 3 main equivalent blocks (A, B, C) and paraffin embedded using a standard histological procedure. Post-mortem examination and gross histological examination verified proper placement of the ICV catheter. Some local tissue damage was apparent due to ICV catheter placement.

**Histopathology and single-labeling immunocytochemistry.** Coronal sections (A, B, C) of brains collected at post-mortem were approximately 3–4 mm in thickness. Regions encompassed within each section were: the anterior section (A; striatum and cortex), the middle section (B; thalamus, dorsal horn of the hippocampus and cortex), and the posterior section (C; thalamus, dorsal and ventral horn of the hippocampus and cortex). Sections were processed and paraffin embedded, then subsequently cut at 10 μm thickness using a microtome passing through the mid-sutria and mid thalamus at 26 and 17 mm, respectfully, to the stereotaxic zero as defined in the stereotaxic atlas for fetal sheep.

Oven dried and xylene deparaffinized sections were rehydrated in a decreasing alcohol series (100%, 95%, 70%), then washed with 0.1 mol/l phosphate buffered saline (PBS). Antigen unmasking was performed using citrate buffer (pH 6.0) by pressure-cooking method (2100 Retriever, Aptum Biologics Ltd, Southampton, UK). Endogenous peroxidase was quenched by incubating the sections with 1% H2O2 in methanol for 30 minutes in darkness. This method was applied for all antibodies, except Olig-2 in which 1% H2O2 in PBS was used. Blocking was performed with 3% (vol/vol) normal goat serum (NGS, Life Technologies Limited, Auckland, NZ) in PBS (NGS-PBS), for 1 h at room temperature. Washed slides were then incubated with corresponding primary and secondary antibodies overnight in 3% NGS-PBS at 4°C.

The following primary antibodies were used. Reactive microglia were labeled with rabbit monoclonal anti-ionized calcium binding adapter molecule-1 (Iba-1) antibody (1:200, AB178680, RRID:AB_2755129, Abcam, Cambridge, England, UK). Reactive astrocytes were labeled with rabbit anti-glial fibrillary acidic protein (GFAP) antibody (1:500, AB68428, RRID:AB_1209224, Abcam). Cells undergoing apoptosis were labeled with rabbit polyclonal anti-cleaved caspase-3, which detects endogenous levels of the large fragment (17/19kDa) of activated caspase-3 resulting from cleavage adjacent to Asp175 (1:200, 9661, RRID:AB_2341188, Cell Signaling Technology Cleaved Caspase-3 (Asp175), Danvers, MA, USA). Immature/mature oligodendrocytes were labeled with mouse monoclonal anti-2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) antibody (1:200, AB6319, RRID:AB_2082593, Abcam). Rabbit monoclonal anti-Olig-2 (1:200, AB109186, RRID:AB_10866130, Abcam) was used as a marker of all cells in the oligodendrocyte lineage. Neuronal nuclei (NeuN) were labeled with rabbit monoclonal anti-NeuN (1:200, AB177487, RRID:AB_2532109, Abcam) and proliferative cells were labeled with mouse monoclonal anti-Ki-67 (M7240, RRID:AB_2142367, Dako, Sydney, AU).

Unbound antibody was removed by washing in PBS then incubating overnight with goat anti-mouse biotin-conjugated IgG (CNPase and Ki-67; BA-9200, RRID:AB_2363171, Vector laboratories, California, USA) or 1:200 goat anti-rabbit (Olig-2, NeuN, Iba-1, GFAP and cleaved caspase-3; BA-1000, RRID:AB_2313606, Vector laboratories) in 3% NGS-PBS, at 4°C. Slides were washed three times with PBS then incubated with 1:200 ExtrAvidin (E2885, Sigma-Aldrich, Auckland, NZ) for 2 hours at room temperature. Sections were treated with dianimobenzidine tetrahydrochloride (DAB, Sigma-Aldrich) to visualize immunoreactivity and nucleus counter-staining was performed using 4′,6-diamidino-2-phenylindole (DAPI, 1:10,000, D1306, ThermoFisher, Victoria, AU). Negative controls in the absence of primary antibody were run in parallel. Sections were then washed in PBS and mounted with citifluor (AF1, Citifluor, Hatfield, USA). All methodology has been described previously.

**Immunofluorescence.** Brain sections (10 μm) were rehydrated and antigen retrieval performed as described above. Slides were washed with PBS + 0.1% Triton X-100 (PBST) to permeabilize the tissue. Blocking was performed using 10% NGS in PBST for 1 hour at room temperature. For assessment of proliferating oligodendrocytes, slides were incubated overnight with 1:200 mouse anti-Ki-67 (M7240) and 1:200 rabbit anti-Olig-2 (AB109186, Abcam) in 10% NGS-PBST, at 4°C. To evaluate microglial polarization, tissue sections were incubated overnight with 1:200 rabbit anti-Iba-1 (AB178680, Abcam) and 1:100 mouse monoclonal anti-human CD163 (MCA1853, RRID:AB_2074540, Bio-Rad, CA, USA) in 10% NGS-PBST, at 4°C. Slides were washed and incubated for 2 hours with corresponding fluorescent-labeled anti-rabbit secondary antibody (1:500, Alexa Fluor 488, Molecular Probes, Life Technologies, Carlsbad, CA, USA) and anti-mouse secondary antibody (1:500, Alexa Fluor 568, Molecular Probes) in 10% NGS-PBST, at room temperature. Nuclei counter-staining was performed using DAPI (1:10,000, D1306, ThermoFisher, Victoria, AU). Negative controls with the primary antibody omitted were run in parallel. Slides were then washed and mounted with citifluor (AF1, Citifluor, Hatfield, USA). All methodology has been described previously.
Image analysis and quantification. Regions of the brain analysed included the subcortical periventricular white matter (PVWM) and intragryral white matter (IGWM) tracts, and the mid-striatum (comprising the caudate nucleus and putamen) on sections taken 26 mm anterior to stereotaxic zero (Fig. 1). The thalamic regions (medial nucleus, MN, and medial geniculate nucleus, MGN), the dentate gyrus (DG) and the cornu ammonis (CA) divisions of the dorsal horn of the anterior hippocampus (CA1/2, CA3, CA4) were evaluated from sections taken 17 mm anterior to the stereotaxic zero. The methodology has been described previously. Whole slide sections were imaged on a Zeiss Axio Imager Z2 microscope with an automated motorized stage (Carl Zeiss AG, Oberkochen, Germany). Serial images were acquired at 10x magnification (0.45 NA, Plan Apochromatic) and collated using the VSlide stitching software (VSViewer, v2.1.117, MetaSystems, Altlußheim, Germany). Regions of interest (ROI) from the whole slide scan were marked by an assessor (K.H.T.C) blinded to the groups by independent coding of slides. Two sections from each animal were counted and averaged. Using ImageJ software (National Institutes of Health, USA, v1.50i), structures of interest were outlined (Fig. 1) and immuno-positive cells were quantified using a macro script customised to individual stains to measure cell density (see Supplementary Figs. S1 & S2). Briefly, for CNPase, GFAP and Iba-1 stains cell bodies were extracted by removing fine cellular processes from background and thresholding with size and circularity filters (sensitivity of automated algorithm versus a human observer (true positive/total actual true): CNPase; 87.4%, GFAP; 89.7%, Iba-1; 89.8%). For cleaved caspase-3, NeuN, Olig-2 and Ki-67 stains, cell nuclei were extracted from background and segmented using size and circularity filters, as well as applying watershed segmentation (sensitivity: cleaved caspase-3; 100%, NeuN; 89.6%, Olig-2; 90.6%, Ki-67; 91.4%). For Olig-2/Ki-67 co-localization, cell nuclei were segmented from individual channels and co-localization was evaluated using the ‘AND’ function (sensitivity: 100%). The full outline of the macro script is provided in Supplementary Fig. 1 and Fig. 2. The range ROI within whole slide scans were 60–150 mm² in the white matter, 70–150 mm² in the striatum (caudate nucleus and putamen), 200–380 μm² within the CA4 hippocampal division, and 25–120 mm² in the thalamic nuclei (MN and MGN). Immunopositivity of NeuN positive cells within the CA1/2, CA3 and DG of the hippocampus displayed high cell density and was quantified by manual assessment of immunostaining at 20x magnification (VSViewer, v2.1.117, MetaSystems). Given the numerous subpopulations of microglia with differing morphological phenotypes and activation states, polarization of activated microglia was manually assessed at 20x magnification to quantify the number of ameboid Iba-1 (activated microglia) and CD163 positive cells. Photomicrographs of single-labeling and immunofluorescent sections were taken at 20x and 40x magnifications, respectively (VSViewer, v2.1.117, MetaSystems).

Cytokine sample collection and analysis. Fetal arterial blood samples were collected for cytokine measurement at baseline (~30 minutes) and following (4, 6, 24, 72, 96, 120, 144, 168 hours) UCO. Cervical puncture was performed at post-mortem for collection of cerebrospinal fluid (CSF). To reduce pre-analytic error, blood samples were immediately placed in pre-chilled tubes with interior coated spray-dried dipotassium ethylenediaminetetraacetic acid (K₂EDTA, Vacutainer, Becton Dickinson UK Ltd, Plymouth, UK), whereas CSF samples were placed in pre-chilled tubes that did not contain additives. To ensure optimum blood/additive ratio, samples were continuously mixed by gentle immersion, centrifuged at 1,500 g for 10 minutes at 4 °C, and stored at −80 °C. Cytokine samples were also centrifuged at 1,500 g for 10 minutes at 4 °C and stored at −80 °C. On the day of analysis, samples were thawed on ice, gently vortexed, and briefly centrifuged before dispensing into separate wells of enzyme-linked immunosorbent assay (ELISA) plates. All samples analysed showed no sign of hemolysis.
IFN-β and IL-1β fetal plasma and CSF levels were determined using in-house bovine and ovine ELISA kits, respectively. IFN-β was detected using antibodies specific to the bovine species (Kingfisher Biotech, St. Paul, MN, USA). Standards were bovine recombinant IFN-β (Kingfisher Biotech) and ranged from 0 to 10 ng/ml with a detection sensitivity of 42 pg/ml. IL-1β was detected using antibodies specific to the ovine species (Kingfisher Biotech). Standards were ovine recombinant IL-1β (Kingfisher Biotech) and ranged from 0 to 10 ng/ml with a detection sensitivity of 13 pg/ml. Tumour necrosis factor-α (TNF-α), IL-6 and IL-10 concentrations were measured using in-house ELISAs as previously described19,37,38.

Statistical analysis. A-priori sample size calculation was conducted using the effect size and variance data from our previous study of CNPase and NeuN loss in the PVWM and caudate nucleus, respectively, following asphyxia21. Based on analysis of images taken at 20x magnification13, our group sizes yielded a statistical power of 80% for both CNPase and NeuN immunoreactivity with an effect size of 2.6 and 1.4, respectively. Fetal biochemical measurements and post-mortem data were evaluated by one-way analysis of variance (ANOVA), followed by Fisher’s least significant difference (LSD) post hoc test when a significant overall effect was found using SPSS v25 (SPSS, Chicago, IL, USA). Cytokine measurements were evaluated by ANOVA, with time as a repeated measure and baseline values as a covariate for split plot analysis using R Statistical Program (v3.3.1 R Statistical Program, The R Foundation for Statistical Computing). Bonferroni post hoc analysis was used to perform pairwise comparisons when a significant overall effect of group or an interaction between group and time was found. Neuropathological data comparisons between groups were performed using ANOVA (v7.03 GraphPad Software, CA, USA). Where significant mean differences were observed between groups and regions, Bonferroni’s post hoc test was used for comparisons. If an effect of region and group was found, the effect of group was assessed for each region separately. All quantitative data are reported as the mean ± standard error of the mean (SEM). The minimum statistical significance threshold was defined as p < 0.05.
Results

Umbral cord occlusion and fetal arterial pressure and heart rate changes. There was no significant difference in the duration of UCO between asphyxia + vehicle and asphyxia + GDQ groups (21.4 ± 0.5 vs. 20.4 ± 0.5 minutes, p > 0.05). In the two occlusion groups, UCO was associated with a significant reduction in both fetal MAP (sham asphyxia: 36.7 ± 1.1 vs. asphyxia + vehicle: 12.6 ± 0.8, and asphyxia + GDQ: 11.7 ± 0.8 mmHg, p < 0.05) and FHR (sham asphyxia: 182.9 ± 6.1 vs. asphyxia + vehicle: 68.7 ± 5.0, and asphyxia + GDQ: 68.7 ± 3.4 bpm, p < 0.05) compared to sham asphyxia, which was not significantly different from each other (p > 0.05).

Fetal biochemistry. There were no significant differences between groups in pH, blood gases, glucose and lactate in the baseline period (Table 1). UCO was associated with marked hypoxemia and metabolic and respiratory acidosis in both occlusion groups (p < 0.05 vs. sham asphyxia). Post-UCO, most variables normalised within a day. However, in the asphyxia + GDQ group, there were transient changes in pH and PaCO₂ values between 120–144 hours post-UCO (p < 0.05 vs. sham asphyxia) and a small reduction in lactate between 72–120 hours post-UCO (p < 0.05 vs. asphyxia).

Post-mortem data. There was no significant difference in fetal body weight or fetal sex ratio between experimental groups at post-mortem (Table 2). Brain weight was reduced in both occlusion groups compared with sham asphyxia (30.1 ± 0.1 g, p < 0.05 vs. sham asphyxia + vehicle; 26.7 ± 0.8, and asphyxia + GDQ: 26.3 ± 1.1 g, p < 0.05). Fetal brain per body weight was reduced in both occlusion groups compared with sham asphyxia (17.0 ± 0.5 vs. asphyxia + vehicle; 13.4 ± 0.8, and asphyxia + GDQ: 13.9 ± 0.5 g/kg, p < 0.05). There was no significant difference in brain weight or brain per body weight between occlusion groups.

Fetal plasma cytokine concentrations. Baseline concentration of cytokines, IL-1β, IL-6, IL-10, TNF-α and IFN-γ, were not significantly different between groups (Fig. 2). Following UCO and throughout the remainder of the experiment, there was no significant difference between groups for IL-1β (Fig. 2A). Post-UCO, the asphyxia + GDQ group was associated with a significant increase in IL-6 concentrations at 6 hours (p < 0.05 vs. sham asphyxia) and 24 hours (p < 0.05 vs. asphyxia + vehicle) (Fig. 2B). In the asphyxia + GDQ group, IL-10 concentrations were markedly higher from 4 hours until 48 hours post-UCO compared to sham asphyxia and asphyxia + vehicle (p < 0.05) (Fig. 2C). TNF-α concentrations in the asphyxia + GDQ group were also significantly greater at 4 hours (p < 0.05 vs. sham asphyxia) and 6 hours post-UCO (p < 0.05 vs. sham asphyxia and asphyxia + vehicle), and were significantly lower between 24–72 and 120–168 hours post-UCO (p < 0.03 vs. asphyxia + vehicle) (Fig. 2D). Lastly, following UCO and throughout the remainder of the experiment, there was no significant difference in fetal plasma IFN-γ concentrations between groups (Fig. 2E).

Table 1. Fetal blood gases, pH and metabolites during the baseline period, asphyxia, and recovery. Data presented as mean ± SEM. Abbreviations: UCO, umbilical cord occlusion; PaCO₂, arterial pressure of carbon dioxide; PaO₂, arterial pressure of oxygen. Statistical significance was determined by one-way ANOVA followed by Fisher's LSD post hoc analysis: *p < 0.05 vs. sham asphyxia; **p < 0.05 vs. asphyxia + vehicle.
Cerebrospinal fluid cytokine concentration. Fetal CSF concentrations of the cytokines IL-6, TNF-α and IFN-β were not significantly different between all three groups (Fig. 3A–C). However, IL-10 concentrations in the asphyxia + GDQ group were significantly higher compared to those of sham asphyxia and asphyxia + vehicle (p < 0.05, Fig. 3D). Concentrations of the pro-inflammatory cytokine IL-1β were below the minimum detection value in all groups (data not shown).

GDQ effects on oligodendrocytes, apoptosis and proliferation. To assess whether GDQ treatment affects oligodendrocyte lineage survival, the cell density of immature and mature oligodendrocytes within the PVWM and IGWM were determined using the oligodendroglial cell marker CNPase. Quantitative assessment revealed that in both occlusion groups, there was no significant change in CNPase positive oligodendrocytes compared to sham asphyxia or between occlusion groups (Figs. 4A and 5A–C). Likewise, in both occlusion groups there was no significant change in the proportion of CNPase/Olig-2 positive cells within the PVWM and IGWM compared to sham asphyxia or between occlusion groups (p > 0.05, data not shown). We next performed an assessment of oligodendrocytes throughout their lineage, including mature myelinating oligodendrocytes, using the cell marker Olig-2. As with CNPase, there was no significant difference in Olig-2 cell density in both occlusion groups within the white matter regions compared to sham asphyxia (Figs. 4B and 5D–F). Analysis of

| Group             | Sex (M:F) | Fetal body weight (kg) | Brain weight (g) | Brain per body weight (g/kg) |
|-------------------|-----------|------------------------|-----------------|-----------------------------|
| Sham asphyxia     | 4: 4      | 1.8 ± 0.1              | 30.1 ± 0.1      | 17.0 ± 0.5                  |
| Asphyxia + vehicle| 3: 4      | 2.0 ± 0.1              | 26.7 ± 0.8*     | 13.4 ± 0.8*                 |
| Asphyxia + GDQ    | 3: 4      | 1.9 ± 0.1              | 26.2 ± 0.9*     | 13.7 ± 0.6*                 |

Table 2. Post-mortem fetal sex ratio, body and brain weight data. Data presented as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Bonferroni's multiple comparisons test: *p < 0.05 vs. sham asphyxia.

Figure 3. Fetal cerebrospinal fluid (CSF) concentration of IL-6 (pg/ml), TNF-α (pg/ml), IFN-β (pg/ml) and IL-10 (pg/ml) in sham asphyxia (n = 8), asphyxia + vehicle (n = 7) and asphyxia + GDQ (n = 7) groups at 7 days post-occlusion are represented in A-D, respectively. Data presented as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Bonferroni's multiple comparisons test: *p < 0.05 sham asphyxia and asphyxia + vehicle vs. asphyxia + GDQ.
cell apoptosis using an antibody that specifically recognizes cleaved caspase-3 (activated caspase-3) revealed no significant change in the number of activated caspase-3 positive cells in the PVWM and IGWM compared to sham asphyxia or between occlusion groups (Figs. 4C and 5G–I).

To evaluate compensatory cellular proliferation, single-labeled immunocytochemistry using the proliferative marker Ki-67 was undertaken. Within the PVWM, both occlusion groups revealed a significant increase in proliferating Ki-67 positive cells (p < 0.04 vs. sham asphyxia, Figs. 4D and 5J–L), although there was no significant difference between occlusion groups. On the other hand, there was no significant change in Ki-67 positive cells within the IGWM. To identify proliferating cells, sections were double-labeled with both Ki-67 and Olig-2. As illustrated in Fig. 6, both occlusion groups revealed a significant increase in proliferating oligodendrocytes within the PVWM (p < 0.002 vs. sham asphyxia, Fig. 6A–C,G) compared to sham asphyxia, but there was no significant difference between the occlusion groups. Similar to the Ki-67 labeling on its own, there was no significant change in proliferating oligodendrocytes within the IGWM (Fig. 6D–F,G).

GDQ effects on density of reactive astrocytes and activated microglia. The possible impact of GDQ on reactive astrogliosis and microglial activation was determined. In both occlusion groups there was no significant change in GFAP positive astrocytes within the PVWM and IGWM compared to sham asphyxia (Fig. 7A,C–E). However, the density of microglia (Iba-1 positive cells) within the PVWM and IGWM was significantly increased in both occlusion groups compared to sham asphyxia (p < 0.05), though there was no significant difference between occlusion groups (Fig. 7B,F–H). Double-labeling immunofluorescence revealed the increase in microglia in both occlusion groups did not represent a significant change in the number of ameboid Iba-1 (activated microglia) / CD163 positive cells within the PVWM and IGWM (Fig. 8).

GDQ effects on neuronal density within hippocampal and selected subcortical regions. The asphyxia + vehicle group exhibited a significant decrease in neuronal density, as visualized by NeuN immunoreactivity, within the striatal caudate nucleus, CA1/2, CA3, CA4, DG of the hippocampus, thalamic MN and MGN compared to sham asphyxia (p < 0.05, Figs. 9A and 10). Similarly, in the asphyxia + GDQ group, among the eight regions assessed, results showed that neuronal density was significantly reduced in the caudate nucleus, CA1/2, DG, and MGN compared to sham asphyxia (p < 0.05). Notably, in the asphyxia + GDQ group there was no significant difference regarding neuronal density in CA3, CA4 and MN regions compared to sham asphyxia.
However, when compared to the asphyxia + vehicle group, neuronal density was significantly reduced in the caudate nucleus (p < 0.05), whereas it was significantly improved in the CA4 hippocampal region (p < 0.05).

The asphyxia + vehicle group revealed a significant increase in the number of apoptotic (activated caspase-3 positive) cells within the caudate nucleus, putamen, CA1/2 and MN regions compared to sham asphyxia (p < 0.05, Figs. 9B and 11). In the asphyxia + GDQ group, activated caspase-3 cell density was not significantly different between groups in all regions assessed apart from the putamen, which showed a significant reduction in caspase-3 positive cells (p < 0.05 vs. asphyxia + vehicle).

---

**Figure 5.** Representative photomicrographs of immature and mature oligodendrocytes (CNPase positive cells, A–C), total oligodendrocytes (Olig-2 positive cells, D–F), apoptotic cells (cleaved caspase-3 positive cells, G,H) and proliferating cells (Ki-67 positive cells, J–L) in the periventricular white matter (PVWM) from sham asphyxia, asphyxia + vehicle and asphyxia + GDQ groups 7 days after umbilical cord occlusion. Magnification 20×. Scale bar is 50 µm.

**Figure 6.** Oligodendrocyte proliferation. Representative photomicrographs of proliferating oligodendrocytes using double immunofluorescent labeling with Ki-67 (red) and Olig-2 (green) within the periventricular (PVWM, A–C) and intragryral white matter (IGWM, D–F) from sham asphyxia (A,D), asphyxia + vehicle (B,E) and asphyxia + GDQ groups (C,F) 7 days after umbilical cord occlusion. Dark blue represents DAPI nuclear counterstain. Arrowheads indicate Ki-67/Olig-2 positive staining. Magnification 40×. Scale bar is 50 µm.

Data depict the density of Olig-2/Ki-67 positive cells within the PVWM and IGWM in sham asphyxia (n = 8), asphyxia + vehicle (n = 7) and asphyxia + GDQ (n = 7) groups (G). Data presented as mean ± SEM. Statistical significance was determined by two-way ANOVA followed by Bonferroni’s multiple comparisons test: *p < 0.05 vs. sham asphyxia.
Discussion

The results of this investigation demonstrated that delayed ICV administration of the TLR7 agonist GDQ was not as protective long-term as it was at 3 days recovery following acute severe asphyxia in the preterm fetal sheep. This is reflected by our data indicating GDQ did not significantly change the number of oligodendrocytes in the white matter despite prevailing increases in the concentration of the anti-inflammatory cytokine IL-10 in the CSF and plasma. Furthermore, GDQ administration ameliorated neuronal injury within the hippocampal CA4 sub region, but was without effect in various subcortical regions and increased neuronal loss within the caudate nucleus of the striatum. These data suggest that although GDQ can elicit central and systemic immunomodulation, it may not contribute to long-term neuroprotection, at least using an acute dosing regimen as has been adopted in the present study.

In the current study, we confirm that asphyxia was associated with induction of microglia within the white matter, with no significant difference in astrocytic cell counts, consistent with previous reports in the preterm fetal sheep. Notably, we found no significant difference in the number of total oligodendrocytes, as indicated by Olig-2 positive cells. These results are in contrast to our previous findings using the same experimental paradigm and dosage regimen, whereby central infusion of the TLR7 agonist GDQ significantly improved survival of not only Olig-2 positive oligodendrocytes, but also CNPase positive oligodendrocytes, 3 days following asphyxia. However, our data is consistent with a previous report speculating net expansion in the pool of oligodendrocytes at 7 days post-asphyxial recovery. Indeed, our finding of robust proliferation of total oligodendrocytes, which includes pre-oligodendrocytes, within the PVWM, as indicated by Olig-2/Ki-67 double-labeling in both asphyxia groups supports this. Nevertheless, while Olig-2 cell density is preserved as a consequence of proliferation of pre-oligodendrocytes following injury, it is associated with failure to terminally differentiate. Moreover in support, studies in the preterm fetal sheep report findings of myelin deficits and diffuse loss of immature or mature oligodendrocytes by 7 days post-asphyxial recovery. Notwithstanding the above concerns, in the present study we did not observe significant changes to immature or mature oligodendrocyte populations, as indicated by the number of CNPase positive cells. Thus, given these findings a thorough examination of the entirety of the oligodendrocyte lineage, including pre-oligodendrocytes and mature myelinating oligodendrocytes, is required to assess the maturational changes following post-asphyxial treatment as well as asphyxia alone.

Figure 7. Effects of GDQ on reactive astrogliosis and microglial activation. Data depict the number of astrocytes (GFAP, A) and microglia (Iba-1, B) in the periventricular white matter (PVWM) and intragyral white matter region (IGWM) in sham asphyxia (n = 8), asphyxia + vehicle (n = 7) and asphyxia + GDQ (n = 7) groups 7 days after umbilical cord occlusion. Data presented as mean ± SEM. Statistical significance was determined by two-way ANOVA followed by Bonferroni’s multiple comparisons test: *p < 0.05 vs. sham asphyxia. Representative photomicrographs of astrocytes (GFAP positive cells, C–E) and microglia (Iba-1 positive cells, F–H) in the PVWM from sham asphyxia, asphyxia + vehicle and asphyxia + GDQ groups. Magnification 20×. Scale bar is 50µm.
Long-term neuronal recovery is also a major end-point of importance. In the present study, asphyxia alone was associated with reduced brain weight and significant neuronal loss in the dorsal striatum caudate nucleus, medial nucleus and medial geniculate nucleus of the thalamus, regions of the dorsal horn of the anterior hippocampus (CA1-4) and dentate gyrus. Such findings agree well with clinical observations of acute asphyxia at birth, whereby moderate to severe damage to subcortical neurons and sparing of the cerebral cortex is detectable by magnetic resonance imaging. Further, neuronal loss was accompanied by ongoing upregulation of caspase-3 positive apoptosis in the subcortical nuclei. This pattern of neuronal injury is comparable with previously reported changes in the subcortical grey matter at 7 days post-asphyxial recovery. Presently, despite conferring partial protection within the hippocampus, post-asphyxial administration of GDQ did not significantly improve neuronal injury, but instead further exacerbated neuronal loss within the caudate nucleus of the striatum. This is unlike our previous finding of acute protection against subcortical injury, which exhibited improved survival of neurons within the dentate gyrus and caudate and medial thalamic nucleus at 3 days following asphyxia. Thus, although GDQ confers early, but transient protection of subcortical neurons, it may not be sustainable long-term beyond the secondary phase of recovery after asphyxia.

The underlying reasons for region-specific exacerbation of neuronal injury are unknown. Vulnerability of the caudate nucleus to HI injury has been reported in both experimental and clinical studies and likely relates to the susceptibility endowed as a result of neuronal NOS expression in adjacent cells associated with oxidative stress and glutamate receptor activity. The caudate nucleus appears selectively protected by nitric oxide inhibition during asphyxia, since evidence suggests it may assist stabilization of cell function and reduction of excitatory events, such as seizures. Moreover, pro-inflammatory cytokines, such as TNF-α, have been shown to increase the production of nitric oxide in co-cultures of neurons and glial cells and potentiate glutamate neurotoxicity. Given this, it is important to note that analysis of fetal plasma in the present study revealed transient induction of both pro-inflammatory and anti-inflammatory cytokines, such as TNF-α, IL-6 and IL-10, between 4–48 hours recovery. Although the temporal expression of pro-inflammatory and anti-inflammatory cytokines was broadly comparable with our previously demonstrated systemic effects of GDQ there were dissimilarities in relation to the magnitude of TNF-α induction. Therefore, speculatively, GDQ induced expression of pro-inflammatory cytokines may have contributed, at least in part, to exacerbated neuronal injury.

In our previous 3 day recovery investigation, GDQ was associated with induction of immunosuppressive M2-like microglial cells, as reflected by an increase in the number of CD163/Iba-1 positive cells within the cerebral white matter. However, presently, GDQ-induced M2-like microglial polarization was not sustained by 7 days post-asphyxial recovery. This observation together with the above summation of evidence suggests the possibility that early, but transient, immunomodulatory responses elicited by GDQ may undermine the long-term histological changes. Consistent with this speculation, acute treatment with potential immunomodulators, such as...
as IL-10, IFN-β and minocycline, are only able to exert early transient neuroprotection against ischemic brain injury that is not sustained in the long-term. Furthermore, while GDQ was associated with higher CSF concentrations of IL-10 at post-mortem, the magnitude achieved (~400 pg/ml) may have been below the threshold for neuroprotection, since concentrations substantially greater (1 ng/ml) do not attenuate cortical neuronal cell death following oxygen-glucose deprivation in vitro. Conversely, there is evidence to support chronic repetitive triggering of TLR7 with periods of treatment-free intervals to be of benefit long-term. For example, in mice repeated administration of R848 (Resiquimod), a synthetic agonist for TLR7, suppressed production of pro-inflammatory cytokines TNF-α and IL-6 and increased production of IL-10. Furthermore, using similar dosage regimens, the TLR7 agonist, Imiquimod, reduced experimental autoimmune encephalomyelitis and increased splenic IFN-β production.

Recent studies have demonstrated that TLR7 agonists can induce neuronal cell death dependent on TLR7. Studies by Lehman and co-authors revealed that TLR7 activation in neurons by endogenous ligands, such as miRNA let-7, can induce significant loss of cortical and striatal neurons in adult mice and this can commence within 3 days after administration, with greater neuronal loss after 2 weeks. Further, in vitro studies of cortical neurons derived from mice demonstrate that TLR7-mediated neuronal death occurs after 4 days following stimulation. Thus, the potential of delayed TLR7-mediated cell death may underlie neuronal injury in subcortical regions that exhibit transient protection. Nevertheless, it is important to note that the effect of TLR7 activation on the immature brain may differ from that of the adult brain and following injury. Effects on the normal brain appear different since activation of TLR7 plays a pivotal role in normal neuronal development and function of the brain and that TLR7 can differentially regulate both neuronal and glial cells according to developmental stages. Thus, further studies are required to evaluate the physiological role of TLR7 within the immature brain and determine whether during injury it may account for enhanced susceptibility to neuronal injury.

Some potential limitations of the current histological approach for assessing neural changes require consideration. Pragmatically, histological assessment of brain injury is classically determined by analysis of small regions within key cerebral structures, as well as subjective quantification of various glial and neuronal cell population by a single assessor. Given the inevitable inconsistencies in area selection across animals, inability to assess non-uniform changes within large structures and potential investigator-to-investigator variability, a robust and

Figure 9. Effects of GDQ on neuronal density and caspase-3 activation within hippocampal and selected subcortical regions. Data depict the effect of GDQ on the density of neurons (NeuN positive cells, A) and apoptotic cells (activated caspase-3 positive cells, B) within the caudate nucleus, putamen, hippocampal divisions cornu ammonis (CA) 1/2, CA3, CA4 and dentate gyrus (DG), thalamic medial nucleus (MN) and medial geniculate nucleus (MGN) in sham asphyxia (n = 8), asphyxia + vehicle (n = 7) and asphyxia + GDQ (n = 7) groups 7 days after umbilical cord occlusion. Data presented as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Bonferroni’s multiple comparisons test: *p < 0.05 vs. sham asphyxia; †p < 0.05 vs. sham asphyxia + vehicle; ‡p < 0.05 vs. sham asphyxia and asphyxia + vehicle.
unbiased method of analysis of extensive structural regions of the brain is required to confirm prior reports of pathological changes. Therefore, in the current study, we utilized a novel automated cell quantification method to assess white matter regions and subcortical grey matter regions. Our current methodology enabled analysis of larger fields of view of approximately 20-50x within the cerebral white matter. We acknowledge that our current methodology may have overlooked potential changes in CNPase immunoreactivity within specific regions of the white matter. Retrospective power calculations showed that our group size yielded a statistical power of 50% with an effect size of 1.2 for CNPase loss. Given the overall trend for reduced number of CNPase positive cells with asphyxia, the lack of statistical significance may, at least in part, relate to the low statistically power owing to high variability between animals and a relatively small cohort of animals. Thus, a larger cohort may be required to comprehensively report changes in oligodendrocytes, in particular for CNPase positive cells, following asphyxia and treatment. Nevertheless, it is important to appreciate that the current method of analysis may provide better representative regional changes in glial cells and neurons within the brain. An additional limitation of this study relates to our failure to demonstrate a significant increase in the anti-inflammatory cytokine IFN-β in association with GDQ treatment, which is in contrast to our previous findings. Such inconsistencies may relate to different ELISA assay platforms employed in each study.

Figure 10. Representative photomicrographs of neurons (NeuN positive cells) in the striatal caudate nucleus (A–C), putamen (D–F), hippocampal divisions cornu ammonis (CA) 1/2 (G–I), CA3 (J–L), CA4 (M–O), dentate gyrus DG (P–R), thalamic medial nucleus (MN, S–U) and medial geniculate nucleus (MGN, V–X) in sham asphyxia, asphyxia + vehicle and asphyxia + GDQ groups 7 days after umbilical cord occlusion. Magnification 20×. Scale bar is 50 µm.
Finally, whether the adverse effects on striatal neurons is a consequence of modulation of existing injury or effect of treatment alone remain unknown. Future studies to examine the effects of GDQ on the normal brain, the impact of drug dosage and the potential to prolong acute immunomodulatory effects with longer or repeated administration are necessary.

**Conclusion**

In conclusion, our findings appear not supportive of a long-term neuroprotective action for delayed ICV administration of the TLR7 agonist, GDQ, following asphyxia in the preterm fetal sheep. This is reflected by our observation that GDQ did not significantly change the number of oligodendrocytes within regions of the white matter vulnerable to injury. Furthermore, whilst GDQ exhibited long-term protective effects within the CA4 region of the hippocampus, it was without effect in various subcortical regions, but did exacerbate neuronal injury within the caudate nucleus. Finally, further studies are required to investigate whether different dosage regimens involving repeated activation of TLR7 may be of benefit long-term.

Received: 21 November 2019; Accepted: 31 March 2020; Published online: 23 April 2020
References

1. Behrman, R. E. & Stith Butler, A. Institute of Medicine Committee on understanding premature birth and assuring healthy outcomes board on health sciences outcomes. Preterm birth: causes, consequences, and prevention, National Academies Press, Washington, DC. 2007.

2. Hutchinson, E. A., De Luca, C. R., Doyle, L. W., Roberts, G. & Anderson, P. J. Group VICS. School-age outcomes of extremely preterm or extremely low birth weight children. Pediatrics. 131(4), e1053–e61 (2013).

3. Hack, M. et al. Outcomes in young adulthood for very-low-birth-weight infants. New England Journal of Medicine. 346(3), 149–57 (2002).

4. Anderson, P. & Doyle, L. W. Group VICS. Neurobehavioral outcomes of school-age children born extremely low birth weight or very preterm in the 1990s. Jama. 289(24), 3264–72 (2003).

5. Volpe, J. J. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. The Lancet Neurology. 8(1), 110–24 (2009).

6. Manuck, T. A. et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. Am J Obstet Gynecol. 215(1), 103.e1–0.e14 (2016).

7. Jacobson S et al. Cooling for newborns with hypoxic ischaemic encephalopathy. status and date: Edited (no change to conclusions), published in. 2013(3).

8. Ryan, M., Lacaze-Masmontel, T. & Mohammad, K. Neuroprotection from acute brain injury in preterm infants. Paediatrics & child health. 23(4), 276–82 (2019).

9. Miller, S., Lee, H. & Gould, J. Hypothermia in very low birth weight infants: distribution, risk factors and outcomes. Journal of Perinatology. 31(S1), S49 (2011).

10. Hagberg, H. et al. The role of inflammation in perinatal brain injury. Nature Reviews. Neurology. 11(4), 192 (2015).

11. Mallard, C., Wang, X. & Hagberg, H. The role of Toll-like receptors in perinatal brain injury. Clinics in perinatology. 36(4), 763–72 (2009).

12. Boonstra, A. et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. The Journal of Immunology. 177(11), 7551–8 (2006).

13. Butchi, N. B., Woods, T., Du, M., Morgan, T. W. & Peterson, K. E. TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. The American journal of pathology. 179(2), 783–94 (2011).

14. Vultaggio A et al. The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10–inducing cytokines. Journal of immunology (Baltimore, Md: 1950). 2011;186(8):4707–15.

15. Forward, N. A., Furlong, S. J., Yang, Y., Lin, T.-J. & Hoskin, D. W. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+ CD25+ T regulatory cells. Journal of leukocyte biology. 87(1), 117–25 (2010).

16. O'Brien, K., Fitzgerald, D., Rostami, A. & Gran, B. The TLR7 agonist, imiquimod, increases IFN-γ production and reduces the severity of experimental autoimmune encephalomyelitis. Journal of neuroimmunology. 221(2–3 101–17. 10–10 (2010).

17. Hayashi, T. et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proceedings of the National Academy of Sciences. 106(8), 2764–9 (2009).

18. Wang, G. et al. TLR7 (Toll-Like Receptor 7) Facilitates Heme Scavenging Through the BTB (Bruton Tyrosine Kinase)–CRT (Calreticulin)–LRP1 (Low-Density Lipoprotein Receptor–Related Protein–1)–Hx (Hemopexin) Pathway in Murine Intracerebral Hemorrhage. Stroke. 49(12), 2020–9 (2018).

19. Dhillon, S. K. et al. Lipopolysaccharide-induced preconditioning attenuates apoptosis and differentially regulates TLRL4 and TLR7 gene expression after ischemia in the preterm ovine fetal brain. Developmental neuroscience. 37(6), 497–514 (2015).

20. Leung, P. Y. et al. Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke. 43(5), 1393–9 (2012).

21. Cho, K. H. T. et al. Protective effects of delayed intraventricular TLR7 agonist administration on cerebral white and gray matter following asphyxia in the preterm fetal sheep. Scientific reports. 9(1), 9562 (2019).

22. Jisa, K. A., Clarey, D. D. & Peeples, E. S. Magnetic Resonance Imaging Findings of Term and Preterm Hypoxic-Ischemic Encephalopathy: A Review of Relevant Animal Models and Correlation to Human Imaging. The open neuroimaging journal. 12, 55 (2018).

23. Riddle, A. et al. Histopathological correlates of magnetic resonance imaging–defined chronic perinatal white matter injury. Annals of neurology. 70(3), 493–507 (2011).

24. Fleiss, B. & Gressens, P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? The Lancet Neurology. 11(6), 556–66 (2012).

25. Geddes R, Vannucci RC, Vannucci SJ. Delayed cerebral atrophy following moderate hypoxia-ischemia in the immature rat. Developmental neuroscience. 23 (2001).

26. McIntosh, G., Baghurst, K. I., Potter, R. & Hetzel, B. Foetal brain development in the sheep. Foetal and neonatal medicine. 19, 103–14 (1979).

27. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS biology. 8(6), e1000412 (2010).

28. Davidson, J. O. et al. Connexin 62 and connexin 43 form hemichannel blockade is neuroprotective after asphyxia in preterm fetal sheep. PLoS One. 9(5), e95558 (2014).

29. Bennet, L. et al. Time and sex dependent effects of magnesium sulphate on post- asphyxial seizures in preterm fetal sheep. Journal of physiology, Paris. 110(23), 6079–92 (2018).

30. Bennet, L., Rossenrode, S., Gunning, M., Gluckman, P. & Gunn, A. The cardiovascular and cerebrovascular responses of the immature fetal sheep to acute umbilical cord occlusion. Journal of physiology, Paris. 517(1), 247–57 (1998).

31. van den Heuij, L. G. et al. Delayed intranasal infusion of human amnion epithelial cells improves white matter maturation after asphyxia in preterm fetal sheep. Journal of Cerebral Blood Flow & Metabolism. 39(2), 223–39 (2019).

32. Barkovich, A. J. & Truwit, C. L. Brain damage from perinatal asphyxia: correlation of MR findings with gestational age. American Journal of Neuroradiology. 11(6), 1087–96 (1990).

33. Yan, E. B. et al. Novel method for in vivo hydroxyl radical measurement by microdialysis in fetal sheep brain in utero. Journal of Applied Physiology. 98(6), 2304–10 (2005).

34. Gluckman, P. D. & Parsons, Y. Stereotaxic method and atlas for the ovine fetal forebrain. J Dev Physiol. 5(2), 101–28 (1983).

35. Colton, C. A. & Wilcock, D. M. Assessing activation states in microglia. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 9(2), 174–91 (2010).

36. Hanisch, U.-K. & Gertig, U. Microglial diversity by responses and responders. Frontiers in cellular neuroscience. 8, 101 (2014).

37. Weaver-Mikaere, L., Gunn, A. J., Mitchell, M. D., Bennet, L. & Fraser, M. LPS and TNF alpha modulate AMPA/NMDA receptor subunit expression and induce PGE2 and glutamate release in preterm fetal ovine mixed glial cultures. Journal of neuroinflammation. 10(1), 916 (2013).

38. Weaver-Mikaere, L., Gibbons, H. M., De Silva, D. & Fraser, M. Primary mixed glial cultures from fetal ovine forebrain are a valid model of inflammation-mediated white matter injury. Developmental neurobiology. 34(1), 30–42 (2012).

39. Drury, P. P. et al. Partial neural protection with prophylactic low-dose melatonin after asphyxia in preterm fetal sheep. Journal of Cerebral Blood Flow & Metabolism. 34(1), 126–35 (2014).
40. Kooime, M. E. et al. Antenatal dexamethasone after asphyxia increases neural injury in preterm fetal sheep. PLoS One. 8(10), e77480 (2013).
41. Buser, J. R. et al. Arrested preoligodendrocyte maturation contributes to myelination failure in premature infants. Annals of neurology. 71(1), 93–109 (2012).
42. Segovia, K. N. et al. Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury. Annals of Neurology: Official. Journal of the American Neurological Association and the Child Neurology Society. 63(4), 520–30 (2008).
43. Huang, B. Y. & Castillo, M. Hypoxic brain injury: imaging findings from birth to adulthood. Radiographics. 28(2), 417–39 (2008).
44. Barkovich, A. J. & Sargent, S. K. Profound asphyxia in the premature infant: imaging findings. American Journal of Neuroradiology. 16(9), 1837–46 (1995).
45. Bennet, L., Dean, J. M., Wassink, G. & Gunn, A. I. Differential effects of hypothermia on early and late epileptiform events after severe hypoxia in preterm fetal sheep. Journal of neurophysiology. 97(1), 572–8 (2007).
46. Wassink, G. et al. Partial white and grey matter protection with prolonged infusion of recombinant human erythropoietin after asphyxia in preterm fetal sheep. Journal of Cerebral Blood Flow & Metabolism. 37(3), 1080–94. (2017).
47. Quillen, P. S. & Ferriero, D. M. Selective vulnerability in the developing central nervous system. Pediatric neurology. 30(4), 227–35 (2004).
48. Drury, P. P. et al. Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. Experimental neurology. 250, 282–92 (2013).
49. Drury, P. P. et al. NOS inhibition during profound asphyxia reduces seizure burden and improves survival of striatal phenotypic neurons in preterm fetal sheep. Neuropharmacology. 83, 62–70 (2014).
50. Chao, C. C., Hu, S., Ehrlich, L. & Peterson, P. K. Interleukin-1 and tumor necrosis factor-α synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brains, behavior, and immunity. 9(4), 355–65 (1995).
51. Chao, C. C. & Hu, S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Developmental neuroscience. 16(3–4), 172–9 (1994).
52. Gelbard, H. A. et al. Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: implications for AIDS neuropathogenesis. Developmental neuroscience. 15(6), 417–22 (1993).
53. Veldhuis, W. B. et al. Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. Journal of Cerebral Blood Flow & Metabolism. 23(9), 1029–39 (2003).
54. Spera, P. A., Ellison, J. A., Feuerstein, G. Z. & Barone, F. C. IL-10 reduces rat brain injury following focal stroke. Neuroscience letters. 251(3), 189–92 (1998).
55. Fox, C. et al. Minocycline Confers Early but Transient Protection in the Immature Brain following Focal Cerebral Ischemia—Reperfusion. Journal of Cerebral Blood Flow & Metabolism. 25(9), 1138–49 (2005).
56. Pérez-de Puig, I. et al. IL-10 deficiency exacerbates the brain inflammatory response to permanent ischemia without preventing resolution of the lesion. Journal of Cerebral Blood Flow & Metabolism. 33(12), 1955–66 (2013).
57. Dietrich, W. D., Busto, R. & Bethel, J. R. Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Experimental neurology. 182(2), 444–50 (1999).
58. Maier, C. M., Yu, F., Nishi, T., Lathrop, S. J. & Chan, P. H. Interferon-β fails to protect in a model of transient focal stroke. Stroke. 37(4), 1116–9 (2006).
59. Sharma, S. et al. IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain research. 1373, 189–94 (2011).
60. Bourquin, C. et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer research. 71(15), 5123–33 (2011).
61. Baenziger, S. et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood. 113(2), 377–88. (2009).
62. Lehmann, S. M. et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nature neuroscience. 15(6), 827 (2012).
63. Lehmann, S.M. et al. Extracellularly delivered single-stranded viral RNA causes neurodegeneration dependent on TLR7. Journal of immunology (Baltimore, Md: 1950). 189(2), 1448–58. (2012).
64. Hung, Y.-F., Chen, C.-Y., Li, W.-C., Wang, T.-F. & Hsueh, Y.-P. Tlr7 deletion alters expression profiles of genes related to neural function and regulates mouse behaviors and contextual memory. Brain, behavior, and immunity. 72, 101–13. (2018).
65. Gallinsky, R. et al. Magnesium sulfate reduces EGF activity but is not neuroprotective after asphyxia in preterm fetal sheep. Journal of Cerebral Blood Flow & Metabolism. 37(4), 1362–73 (2017).

Acknowledgements

We are indebted to Ms Maree Schollum for providing excellent animal husbandry, anesthesia and surgical management. This research was supported by grants awarded to MF (corresponding author) from the Health Research Council of New Zealand (No. 18/183), Auckland Medical Research Foundation, Cure Kids (No. 3581), Lottery Health Research (No. R-LHR-2017-48693), Maurice and Phyllis Paykel Trust and the Barbara Basham Doctoral Scholarship - Auckland Medical Research Foundation awarded to KHTC (No. 1216004)

Author contributions

M.F. and K.H.T.C. conceived the hypothesis, experimental design and analysis protocols and were responsible for surgical and experimental manipulation. The data analysis and first draft of the paper were undertaken by K.H.T.C., P.V.A. and K.H.T.C. developed the macro script for image analysis. K.H.T.C. performed tissue processing, immunohistochemistry and image analysis. N.Z. and M.F. performed cytokine immunoaassays. B.X. provided surgical support. The final submitted article has been revised and approved by all authors.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63770-6.

Correspondence and requests for materials should be addressed to M.F.

Reprints and permissions information is available at www.nature.com/reprints.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020